Matsuo, Hidemasa
Kamada, Mayumi
Imamura, Akari
Shimizu, Madoka
Inagaki, Maiko
Tsuji, Yuko
Hashimoto, Motomu
Tanaka, Masao
Ito, Hiromu
Fujii, Yasutomo
Funding for this research was provided by:
Japan Society for the Promotion of Science (KAKENHI (18K12103))
Article History
Received: 20 December 2021
Accepted: 22 April 2022
First Online: 4 May 2022
Competing interests
: The department in which M.H. and H.I. retired from and M.T. currently works received financial support from Nagahama city, Toyooka city, and five pharmaceutical companies (Mitsubishi Tanabe Pharma, Chugai Pharmaceutical, UCB Japan, Ayumi, and Asahi Kasei Pharma). M.H. receives research grants and/or speaker fees from Bristol-Myers, Eisai, Eli Lilly, Mitsubishi Tanabe, and Novartis Pharma. H.I. receives research grants from Bristol-Myers, Eisai, Mochida, and Taisho. The KURAMA cohort study is supported by a grant from Daiichi-Sankyo. M.T. has received research grants and/or speaker fees from AbbVie GK, Asahi Kasei Pharma Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Corp., Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Pfizer Inc., UCB Japan Co., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., Novartis Pharma K.K., Taisho Pharma Co., Ltd. The present study was investigator-initiated. These companies played no role in study design, data collection or analysis, writing of the manuscript, or the decision to submit for publication. H.M., M.K., A.I., M.S., M.I., Y.T, and Y.F. declare no competing interests.